Edwards Lifesciences (EW)
(Real Time Quote from BATS)
$66.04 USD
-0.29 (-0.44%)
Updated Sep 25, 2024 12:27 PM ET
4-Sell of 5 4
D Value F Growth F Momentum F VGM
Cash flow Statements
Fiscal Year End for Edwards Lifesciences Corporation falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 1,399.40 | 1,521.90 | 1,503.10 | 823.40 | 1,046.90 |
Depreciation/Amortization & Depletion | 144.90 | 139.60 | 134.80 | 107.20 | 89.30 |
Net Change from Assets/Liabilities | -493.30 | -376.40 | 174.50 | -228.30 | -180.30 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | -155.20 | -66.90 | -80.30 | 352.00 | 223.50 |
Net Cash From Operating Activities | 895.80 | 1,218.20 | 1,732.10 | 1,054.30 | 1,179.40 |
Property & Equipment | -253.00 | -244.60 | -325.80 | -407.00 | -254.40 |
Acquisition/ Disposition of Subsidiaries | -125.20 | -109.60 | -13.10 | -10.00 | -135.20 |
Investments | 640.30 | 689.80 | -1,350.10 | -74.70 | -158.20 |
Other Investing Activities | -88.30 | -83.30 | -33.50 | -39.40 | -48.00 |
Net Cash from Investing Activities | 173.80 | 252.30 | -1,722.50 | -531.10 | -595.80 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | -879.60 | -1,580.70 | -354.20 | -484.90 | -102.80 |
Issuance (Repayment) of Debt | -0.30 | -0.20 | -1.80 | -0.80 | -10.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 168.90 | -3.60 | -0.30 | -1.20 | -2.80 |
Net Cash from Financing Activities | -711.00 | -1,584.50 | -356.30 | -486.90 | -115.60 |
Effect of Exchange Rate Changes | 16.80 | 19.20 | 13.90 | -20.50 | -3.00 |
Net Change In Cash & Equivalents | 375.40 | -94.80 | -332.80 | 15.80 | 465.00 |
Cash at Beginning of Period | 772.60 | 867.40 | 1,200.20 | 1,184.40 | 714.10 |
Cash at End of Period | 1,148.00 | 772.60 | 867.40 | 1,200.20 | 1,179.10 |
Diluted Net EPS | 2.30 | 2.44 | 2.38 | 1.30 | 1.64 |
Fiscal Year End for Edwards Lifesciences Corporation falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 716.00 | 351.00 | 1,399.40 | 1,029.70 | 646.00 |
Depreciation/Amortization & Depletion | 78.10 | 38.50 | 144.90 | 108.20 | 71.30 |
Net Change from Assets/Liabilities | -468.00 | -453.80 | -493.30 | -284.20 | -283.50 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | -8.10 | 10.80 | -155.20 | -94.50 | -86.10 |
Net Cash From Operating Activities | 318.00 | -53.50 | 895.80 | 759.20 | 347.70 |
Property & Equipment | -150.70 | -65.30 | -253.00 | -164.70 | -109.40 |
Acquisition/ Disposition of Subsidiaries | -10.80 | -10.80 | -125.20 | -156.20 | -156.20 |
Investments | 397.70 | 164.00 | 640.30 | 546.50 | 375.70 |
Other Investing Activities | -48.30 | -24.80 | -88.30 | -65.90 | -39.40 |
Net Cash from Investing Activities | 187.90 | 63.10 | 173.80 | 159.70 | 70.70 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | -41.90 | 61.90 | -879.60 | -294.50 | -154.10 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | -0.30 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 7.00 | -0.20 | 168.90 | -3.30 | -0.40 |
Net Cash from Financing Activities | -34.90 | 61.70 | -711.00 | -297.80 | -154.50 |
Effect of Exchange Rate Changes | 39.10 | 9.70 | 16.80 | 20.20 | 11.00 |
Net Change In Cash & Equivalents | 510.10 | 81.00 | 375.40 | 641.30 | 274.90 |
Cash at Beginning of Period | 1,148.00 | 1,148.00 | 772.60 | 772.60 | 772.60 |
Cash at End of Period | 1,658.10 | 1,229.00 | 1,148.00 | 1,413.90 | 1,047.50 |
Diluted Net EPS | 0.61 | 0.58 | 0.61 | 0.63 | 0.50 |